charles arthur peloquin, pharm.d. curriculum vitae · charles a. peloquin page 7 bibliography...

CHARLES ARTHUR PELOQUIN, PHARM.D.

CURRICULUM VITAE

Personal

Present Rank: Professor

Citizenship: USA

Educational History

12/81 Bachelor of Science (Magna cum Laude)

University of Connecticut

5/86 Doctor of Pharmacy

Philadelphia College of Pharmacy and Science

Professional History

5/80 – 9/80 Medicinal Chemist

5/81 – 9/81 University of Connecticut School of Pharmacy

Storrs, CT

12/81 – 7/82 Intern in Pharmacy

Saint Francis Hospital and Medical Center

Hartford, CT

7/82 – 6/83 A.S.H.P. Resident in Hospital Pharmacy

Duke University Medical Center

Durham, NC

7/83 – 2/84 Clinical Pharmacist, General Surgery


Durham, NC

3/84 – 8/84 Clinical Pharmacist, General Medicine


Durham, NC

8/84 – 3/85 Staff Pharmacist

Thomas Jefferson University Hospital

Philadelphia, PA

7/86 – 8/88 A.C.C.P. Fellow, Infectious Diseases and Pharmacokinetics

The Clinical Pharmacokinetics Laboratory

Millard Fillmore Hospital, Buffalo, NY

Charles A. Peloquin

Professional History (continued)

7/88 – 3-09 Director, Infectious Disease Pharmacokinetics Laboratory

National Jewish Medical and Research Center

1400 Jackson Street, Denver, CO 80206

7/88 Assistant Faculty Member, Department of Medicine

4/94 Associate Faculty Member, Department of Medicine

7/01 Senior Faculty Member, Department of Medicine

National Jewish Medical and Research Center

9/88 – 12/94 Adjoint Assistant Professor of Pharmacy

1/95 – 11/01 Adjoint Associate Professor of Pharmacy

11/01 – 9/05 Adjoint Professor of Pharmacy

9/05 – 3/09 Clinical Professor of Pharmacy

University of Colorado School of Pharmacy, Denver, CO

7/93 – 12/94 Adjoint Assistant Professor of Medicine

1/95 – 11/01 Adjoint Associate Professor of Medicine

11/01 – 9/05 Adjoint Professor of Medicine

9/05 – 3/09 Clinical Professor of Medicine, Division of Infectious Diseases

University of Colorado School of Medicine, Denver, CO

3/09 – present Professor, and

Director of the Infectious Disease Pharmacokinetics Laboratory,

College of Pharmacy, and Emerging Pathogens Institute,

University of Florida, Gainesville, FL

Professional Licenses (Registered Pharmacist) 1982 State of Connecticut (#5884)

1984 Commonwealth of Pennsylvania (inactive)

1989 State of Colorado (#12831, inactive)

2009 State of Florida Clinical Lab Technologist, LTD (#TNL 42669)

Honors and Awards

1980-present Rho Chi Honor Society

1981 University of Connecticut Honor Scholar

1987-1988 ACCP Infectious Disease Research Fellow

Professional Affiliations 1982-2004 American Society of Health Systems Pharmacists

1989-2003 Colorado Society of Hospital Pharmacists

1995-2005 International Union Against Tuberculosis and Lung Disease

1986-present American College of Clinical Pharmacy

1990-present American Society of Microbiology

1991-present Society of Infectious Disease Pharmacists

2004-present International Society of Antimicrobial Pharmacology

Charles A. Peloquin

Journal Referee:

Regular: 1990 - present Pharmacotherapy

1997 - present International Journal of Tuberculosis and Lung Disease

1997 - present Clinical Infectious Diseases

1998 - present Antimicrobial Agents and Chemotherapy

2001 - present Journal of Antimicrobial Chemotherapy

Teaching Activities

2010 - present College of Pharmacy, University of Florida

Undergraduate Lectures:

Pharmacotherapy III and V, Infectious Diseases

2010 – present Student laboratory rotations

Clinical Pharmacy Resident

Shaun Berning, Pharm.D.

June 1991 – May 1992

Current: Medical Science Liaison

Ortho Biotech

Fellows / Research Associates

Amy Bulpitt, B.S. Pharmacy, R.Ph.

June 1996 to July 1997

NIH RO1 AI37845 Research Associate

Current: Pharmacist, Swedish Medical Center, Denver

Rocsanna Namdar, Pharm.D.



Current: Assistant Professor, University of Colorado College of Pharmacy

Rebecca Malone, Pharm.D.


FDA Orphan Product Division FD-R-000812-01

Research Associate

Current: Clinical Pharmacist, University of Arizona, Tucson, AZ

Barbara Auclair, Pharm.D.

November 1998 to November 1999


Current: Pharmacist, Greenville, SC

Charles A. Peloquin

Fellows / Research Associates

Min Zhu, Ph.D.

December 1999 to September 2000


Current: Associate Director, Strategic Modeling & Simulation,

Clinical Discovery, Bristol Myers Squibb Company, Princeton, NJ

Bryan McGee, Pharm.D.

September 2007 to present

CU HIV Training Grant

Graduate Students

Eric Egelund, Pharm.D.

August 2010 to present

, Pharm.D.

August 2010 to present

Annual Continuing Education

All requirements met for Pharmacist’s license since 1981

Charles A. Peloquin

Bibliography

A. Original research papers published in refereed journals

(115 papers: 20 first author, 29 senior author, 66 other)

1. Nix DE, Sands M, Peloquin CA, Vari AJ, Cumbo TJ, Vance JW, Fracasso JF, Schentag JJ. Dual

individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract

infections. American Journal of Medicine 1987; 82(suppl 4A):352.

2. Peloquin CA, Cumbo TJ, Nix DE, Sands MF, Schentag JJ. Evaluation of intravenous

ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma

concentrations, organisms, MIC, and clinical condition on bacterial eradication. Archives if

Internal Medicine 1989; 149: 2269-2273.

3. Peloquin CA, James GT, McCarthy EA. Improved high-performance liquid chromatographic

assay for the determination of ethionamide in serum. Journal of Chromatography 1991, 563:

472-475.

4. Peloquin CA, Cumbo TJ, Schentag JJ. Kinetics and dynamics of tobramycin action in

patients with bacteriuria given single doses. Antimicrobial Agents and Chemotherapy 1991; 35:

1191-1195.

5. Peloquin CA, James GT, McCarthy EA, Goble M. Pharmacokinetics of ethionamide

suppositories. Pharmacotherapy 1991; 11: 359-363.

6. Gordon SM, Horsburgh CR, Peloquin CA, Havlik JA, Metchock B, Heifets L, McGowan JE,

Thompson SE. Low serum levels of oral antimycobacterial agents in patients with

disseminated Mycobacterium avium complex disease. Journal of Infectious Diseases 1993; 168:

1559-1562.

7. Peloquin CA, Henshaw TL, Huitt GA, Berning, SE, Nitta AT, James GT. Pharmacokinetic

evaluation of p-aminosalicylic acid granules. Pharmacotherapy 1994; 14: 40-46, and correction:

Pharmacotherapy 1994; 14:(4) P-2.

8. Peloquin CA, James GT, Craig LD, Kim M, McCarthy EA, Iklé DN, Iseman MD.

Pharmacokinetic evaluation of aconiazide, a potentially less toxic isoniazid pro-drug.

Pharmacotherapy 1994; 14: 415-423.

9. Fish DN, Bainbridge JL, Peloquin CA. Variable disposition of ciprofloxacin in critically ill

patients undergoing continuous arteriovenous hemodiafiltration. Pharmacotherapy 1995; 15:

236-245.

10. Berning SE, Madsen L, Iseman MD, Peloquin CA. Long-term safety of ofloxacin and

ciprofloxacin in the treatment of Mycobacterial infections. American Journal of Respiratory and

Critical Care Medicine 1995; 151: 2006-2009.

Charles A. Peloquin

Bibliography (continued)

A. Original research papers published in refereed journals (continued)

11. Elliott AM, Berning SE, Iseman MD, Peloquin CA. Failure of drug penetration and

acquisition of drug resistance in chronic tuberculous empyema. Tubercle and Lung Disease

1995; 76: 463-467.

12. Stetter MD, Peloquin CA. Isoniazid and rifampin therapy failure in a Colobus monkey

(Colobus guereza caudatus). Journal of Zoo and Wild Life Medicine 1995; 26: 152-154.

13. Peloquin CA, Berning SE, Madsen L, Iseman MD. Ofloxacin and Ciprofloxacin in the

Treatment of Mycobacterial Infections: Development of Resistance and Drug Interactions.

Journal of Infectious Disease Pharmacotherapy 1995; 1: 45-65.

14. Peloquin CA, Nitta AT, Burman WJ, Brudney KF, Miranda-Massari JR, McGuinness ME,

Berning SE, Gerena GT. Incidence of low anti-tuberculosis drug concentrations in patients with

AIDS. Annals of Pharmacotherapy 1996; 30: 919-925.

15. Peloquin CA, Nitta AT, Berning SE, Iseman MD, James GT. Pharmacokinetic evaluation of

thiacetazone. Pharmacotherapy 1996; 16: 735-741.

16. Peloquin CA, Berning SE. Evaluation of the Drug Interaction between Clarithromycin and

Rifampin. Journal of Infectious Disease Pharmacotherapy. 1996; 2: 19-35.

17. Hafner R, Cohn JA, Wright DJ, Dunlap NE, Egorin MJ, Enama ME, Muth K, Peloquin CA,

Mor N, Heifets LB and the DATRI 008 Study Group. Early Bactericidal Activity of Isoniazid in

Pulmonary Tuberculosis: Optimization of Methodology. Am J Respir Crit Care Med 1997; 156:

918-923.

18. Peloquin CA, Jaresko GS, Yong CL, Keung ACF, Bulpitt AE, Jelliffe RW. Population

Pharmacokinetic Modeling of Isoniazid, Rifampin, and Pyrazinamide. Antimicrobial Agents and

Chemotherapy 1997; 41: 2670-2679.

19. Cheng KL, Nafziger AN, Peloquin CA, Amsden GW. Effect of grapefruit juice on

clarithromycin pharmacokinetics. Antimicrobial Agents and Chemotherapy. 1998; 42: 927-929.

20. Amsden GW, Cheng KL, Peloquin CA, Nafziger AN. Oral cimetidine prolongs clarithromycin

absorption. Antimicrobial Agents and Chemotherapy. 1998; 42: 1578-1580.

21. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, James GT, Nix DE. Pharmacokinetics of

Pyrazinamide Under Fasting Conditions, with Food, and with Antacids. Pharmacotherapy 1998;

18: 1205-1211.

22. Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of Rifampin Under

Fasting Conditions, with Food, and with Antacids. Chest 1999; 115: 12-18.

Charles A. Peloquin



23. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of

Ethambutol Under Fasting Conditions, with Food, and with Antacids. Antimicrobial Agents and

Chemotherapy 1999, 43; 568-572.

24. Harbeck RJ, Worthen GS, Lebo TD, Peloquin CA. Clofazimine Crystals in the Cytoplasm of

Pulmonary Macrophages. Annals of Pharmacotherapy 1999; 33: 250.

25. Peloquin CA, Berning SE, Huitt GA, Childs JM, Singleton MD, James GT. Once-Daily and

Twice-Daily Dosing of p-Aminosalicylic Acid (PAS) Granules. American Journal of Respiratory

and Critical Care Medicine 1999, 159: 932-934.

26. Garey KW, Peloquin CA, Godo PG, Nafziger AN, Amsden GW. Lack of effect of

zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-

hydroxyclarithromycin in healthy volunteers. Antimicrob Agents Chemother 1999;43:1152-5.

27. Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA. The effect of hemodialysis on

isoniazid, rifampin, pyrazinamide, and ethambutol. Am J Respir Crit Care Med 1999; 159: 1580-

1584.

28. Wimsatt J, Johnson J, Mangone BA, Tothill A, Peloquin CA. Clarithromycin

pharmacokinetics in the desert tortoise (G. agassizii) - Single and preliminary multiple dose

studies. Journal of Zoo and Wild Life Medicine 1999; 30: 36-43.

29. Peloquin CA, Namdar R, Dodge AA, Nix DE. Pharmacokinetics of Isoniazid Under Fasting

Conditions, with Food, and with Antacids. International Journal of Tuberculosis and Lung

Disease. 1999; 3: 703-710.

30. Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA. The effect of hemodialysis on

cycloserine, ethionamide, para-aminosalicylate, and clofazimine. Chest 1999; 116: 984-990.

31. DeVincenzo JP, Berning SE, Peloquin CA, Husson RN. Multidrug-resistant tuberculous

meningitis: Clinical problems and concentrations of second-line anti-tuberculous medications.

Annals of Pharmacotherapy 1999; 33: 1184-1188.

32. Auclair B, Berning SE, Huitt GA, Peloquin CA. Potential interaction between itraconazole

and clarithromycin. Pharmacotherapy 1999; 19: 1439-1444.

33. Gilljam M, Berning SE, Peloquin CA, Strandvik B, Larsson LO. Therapeutic drug

monitoring in patients with cystic fibrosis and mycobacterial disease. Eur Respir J 1999; 14:

347-351.

Charles A. Peloquin



34. Tran JQ, Ballow CH, Forrest A, Hyatt JM, Sands MF, Peloquin CA, Schentag JJ.

Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial

pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and

pharmacodynamic variables. Journal of Antimicrobial Chemotherapy 2000; 45, Topic T2, 9-17.

35. Anisimova Y, Gelperina S, Peloquin C, Heifets, L. Nanoparticles as antituberculosis drug carriers:

effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages. J

Nanoparticle Res 2000; 2; 165-671.

36. Auclair B, Nix DE, Adam RD, James GT, Peloquin CA. Pharmacokinetics of Ethionamide under

Fasting Conditions, with Orange Juice, Food, and Antacids. Antimicrobial Agents and Chemotherapy

2001, 45: 810-814.

37. Shaikh ZHA, Peloquin CA, Ericsson CD. Successful treatment of vancomycin-resistant

Enterococcus faecium meningitis with linezolid: case report and literature review. Scandinavian Journal

of Infectious Diseases 2001; 33: 375-379.

38. Zhu M, Nix DE, Adam RD, Childs JM, Peloquin CA. Pharmacokinetics of Cycloserine under

Fasting Conditions, with Orange Juice, Food, and Antacids. Pharmacotherapy 2001; 21: 891-897.

39. Zhu M, Burman WJ, Jaresko GS, Berning SE, Jelliffe RJ, Peloquin CA. Population

Pharmacokinetics of Intravenous and Intramuscular Streptomycin in Patients with Tuberculosis.


40. Peloquin CA, Zhu M, Adam RD, Godo, PG, Nix DE. Pharmacokinetics of p-Aminosalicylate under

Fasting Conditions, with Orange Juice, Food, and Antacids. Annals of Pharmacotherapy 2001; 35: 1332-

1338.

41. Reid J, Marciniuk D, Peloquin CA, Hoeppner V. Pharmacokinetics of Antituberculosis Medications

Delivered via Percutaneous Gastrojejunostomy Tube. Chest 2002; 121: 281-284.

42. Zhu M, Stambaugh JJ, Berning SE, Bulpitt AE, Hollender ES, Narita M, Ashkin D, Peloquin CA.

Ofloxacin Population Pharmacokinetics in Patients with Tuberculosis. Int J Tuber Lung Dis 2002; 6:

503-509.

43. Zhu M, Starke JR, Burman WJ, Steiner P, Stambaugh JJ, Ashkin D, Bulpitt AE, Berning SE,

Peloquin CA. Population pharmacokinetic modeling of pyrazinamide in children and adults with

tuberculosis. Pharmacotherapy 2002; 22: 686-695.

44. Zhu M, Namdar R, Stambaugh JJ, Starke JR, Bulpitt AE, Berning SE, Peloquin CA. Population

pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis 2002; 82: 91-96.

Charles A. Peloquin



45. Spradling P, Drociuk D, McLaughlin S, Lee LM, Peloquin CA, Gallicano K, Pozsik C, Onorato I,

Ridzon R. Drug-drug interactions in inmates treated for human immunodeficiency virus and

Mycobacterium tuberculosis infection or disease: An institutional tuberculosis outbreak. Clinical

Infectious Diseases 2002; 35: 1106-1112.

46. Manley HJ, McClaran ML, Bedenbaugh A, Peloquin CA. Linezolid stability in peritoneal dialysis

solutions. Peritoneal Dialysis International 2002; 22: 419-422.

47. Auclair B, Mikota SK, Peloquin CA, Aguilar R, Maslow JN. Population pharmacokinetics of

antituberculous drugs and treatment of Mycobacterium bovis infection in bongo antelope (Tragelaphus

eurycerus isaaci). J Zoo Wildl Med 2002; 33: 193-203.

48. Gunderson BW, Ibrahim KH, Peloquin CA, Hovde LB, Rotschafer JC. Comparison of Linezolid

Activity Under Aerobic and Anaerobic Conditions Against Methicillin-Resistant Staphylococcus aureus

and Vancomycin-Resistant Enterococcus faecium. Antimicrobial Agents and Chemotherapy 2003; 47:

398-399.

49. Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, Khan A, Weis S, King B, Shah N,

Hodge T and the Tuberculosis Trials Consortium. Low Isoniazid Concentration Associated with

Outcome of Tuberculosis Treatment with Once-Weekly Isoniazid and Rifapentine. Am J Respir Crit

Care Med. 2003 Jan 16 [e-pub ahead of print]; print version Am J Respir Crit Care Med. 2003; 167:

1341-1347.

50. Kraft MD, Pasko D, DePestel DD, Ellis J, Peloquin CA, Mueller BA. Linezolid Clearance During

Continuous Venovenous Hemodiafiltration: A Case Report. Pharmacotherapy 2003, 23: 1071-1075.

51. DePestel DD, Peloquin CA, Carver PL. Peritoneal Fluid Concentrations of Linezolid in the

Treatment of Vancomycin-Resistant Enterococcus faecium Peritonitis. Pharmacotherapy 2003; 23:

1322-1326.

52. Tsapis N, Bennett D, O’Driscoll K, Shea K, Lipp MM, Fu K, Clarke RW, Deaver D, Yamins D,

Wright J, Peloquin CA, Weitz DA, and Edwards DA. Direct lung delivery of para-aminosalicylic acid

by aerosol particles. Tuberculosis 2003; 83: 379-385.

53. Perlman DC, Segal Y, Rosenkranz S, Rainey PM, Peloquin CA, Remmel RP, Chirgwin K, Salomon

N, Hafner R for the ACTG 309 Team. The clinical pharmacokinetics of pyrazinamide in HIV-infected

persons with tuberculosis. Clin Infect Dis 2004; 38: 556-564.

Charles A. Peloquin



54. Weiner M, Bock

N, Peloquin

CA, Burman

WJ, Khan

A, Vernon

A, Zhao

Z, Weis

S, Sterling

T,

Hayden K, Goldberg S

and the Tuberculosis Trials Consortium. Pharmacokinetics of Rifapentine 600,

900 and 1,200 mg during Once-Weekly Tuberculosis Therapy. American Journal of Respiratory and

Critical Care Medicine. published ahead of print on February 12, 2004 as doi:10.1164/rccm.200311-

1612OC; print version American Journal of Respiratory and Critical Care Medicine 2004; 169: 1191-

1197.

55. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD,

Cook JL, Curran-Everett D. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of

mycobacterial diseases. Clinical Infectious Diseases 2004; 38: 1538-1544.

56. Nix DE, Zhu M, Adam RD, Godo PG, Peloquin CA. Pharmacokinetics of Clofazimine under

Fasting Conditions, with Orange Juice, Food, and Antacids. Tuberculosis 2004; 84: 365-373.

57. Zhu M, Burman WJ, Starke JR, Stambaugh JJ, Steiner P, Bulpitt AE, Ashkin D, Auclair B, Berning

SE, Jelliffe RW, Jaresko GS, Peloquin CA. Population pharmacokinetic modeling of ethambutol in

children and adults with tuberculosis. International Journal of Tuberculosis and Lung Disease 2004; 8:

1360-1367.

58. Maslow JN, Mikota SK, Zhu M, Isaza R, Peddie LR, Dunker F, Peddie J, Riddle H, Peloquin CA.

Population Pharmacokinetics of Isoniazid (INH) in the treatment of Mycobacterium tuberculosis

among Asian and African Elephants (Elephas maximus and Loxodonta africana). Journal of Veterinary

Pharmacology and Therapeutics 2005; 28: 21-27.

59. Stein GE, Schooley S, Peloquin CA, Kak V, Havlichek DH, Citron DM, Tyrrell KL, Goldstein EJC.

Pharmacokinetics and Pharmacodynamics of Linezolid in Obese Patients with Cellulitis. Annals of


60. Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A, Jones B S, Silva-Trigo C,

Zhao Z, Hodge T and the Tuberculosis Trials Consortium. Association Between Acquired Rifamycin

Resistance and the Pharmacokinetics of Rifabutin and Isoniazid among Patients with HIV and

Tuberculosis. Clinical Infectious Diseases 2005; 40: 1481-1491.

61. Maslow JN, Mikota SK, Zhu M, Riddle H, Peloquin CA. Pharmacokinetics of Ethambutol (EMB)

in Elephants. Journal of Veterinary Pharmacology and Therapeutics 2005; 321-323.

62. Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold A, Lockman S, Oyeri R,

Talbot E, Kenyon T, Moetti T, Moffat H, Peloquin CA. Serum Concentrations of

Antimycobacterial Drugs in Patients with Pulmonary Tuberculosis in Botswana. Clinical

Infectious Diseases 2005; 41: 461-469.

Charles A. Peloquin



63. Ciulla TA, Comer GM, Peloquin CA, Wheeler J. Human vitreous distribution of linezolid after a

single oral dose. Retina. 2005; 25: 619-624.

64. Rosenthal IM, Williams K, Tyagi S, Vernon AA, Peloquin CA, Bishai WR, Grosset JH,

Nuermberger EL. Weekly Moxifloxacin and Rifapentine is More Active than the Denver Regimen in

Murine Tuberculosis. Am J Respir Crit Care Med 2005; 172: 1457-1462. [Epub Sept 2005]

65. Zhu M, Maslow JN, Mikota SK, Isaza R, Dunker F, Riddle H, Peloquin CA. Population

Pharmacokinetics of Pyraziamide in Elephants. Journal of Veterinary Pharmacology and Therapeutics J

Vet Pharmacol Ther 2005; 28: 403-409.

66. Weiner M, Benator D, Peloquin CA, Burman W, Vernon A, Engle M, Khan A, Zhao Z and the

Tuberculosis Trials Consortium. Evaluation of the drug interaction between rifabutin and efavirenz in

patients with HIV infection and tuberculosis. Clinical Infectious Diseases 2005; 41: 1343-1349. [Epub

Sept 2005]

67. Perlman DC, Segal Y, Rosenkranz S, Rainey PM, Remmel RP, Salomon N, Hafner R Peloquin CA

for the AIDS Clinical Trials Group 309 Team. The clinical pharmacokinetics of rifampin and

ethambutol in HIV-infected persons with tuberculosis. Clinical Infectious Diseases 2005; 41: 1638-

1647.

68. Rosenthal IM, Williams K, Tyagi S , Peloquin CA, Vernon AA, Bishai WR, Grosset JH,

Nuermberger EL. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J

Respir Crit Care Med 2006 Mar 30; [Epub ahead of print]; Am J Respir Crit Care Med 2006; 174: 94-

101.

69. Johnson JL, Hadad

DJ, Boom

WH, Daley

CL, Peloquin

CA, Eisenach

KD, Jankus

DD, Debanne

SM,

Charlebois ED, Maciel

E, Palaci

M, Dietze

R. Early and Extended Early Bactericidal Activity of

Levofloxacin, Gatifloxacin and Moxifloxacin in Pulmonary Tuberculosis. Int J Tuber Lung Dis 2006;

10: 605-612.

70. Mauro LS, Peloquin CA, Schmude K, Assaly R, Malhotra D. Clearance of linezolid via continuous

venovenous hemodiafiltration. Am J Kidney Dis. 2006; 47: e83-86.

71. Nuermberger E, Rosenthal

I, Tyagi

S, Williams

KN, Almeida

D, Peloquin

CA, Bishai

WR, Grosset

JH. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in the murine

model of tuberculosis. Antomicrobial Agents and Chemotherapy 2006; 50: 2621-2625.

72. Peloquin CA, Maslow JN, Mikota SK, Forrest A, Dunker F, Isaza R, Peddie LR, Dunker F, Peddie

J, Zhu M. Dose Selection and Pharmacokinetics of Rifampin in Elephants for the Treatment of

Tuberculosis. Journal of Veterinary Pharmacology and Therapeutics. 2006; 29:581-5.

Charles A. Peloquin



74. Pinheiro VGF, Ramos LMA, Monteiro

HSA, Barroso EC, Bushen OY, Façanha MC,

Peloquin CA, Guerrant RL, Lima AAM. Intestinal Permeability and Malabsorption of Rifampin

and Isoniazid in Active Pulmonary Tuberculosis. Braz J Infect Dis. 2006 Dec;10(6):374-9.

75. Weiner M, Burman W, Luo CC, Peloquin CA, Engle M, Goldberg S, Agarwal V, Vernon A. Effects

of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob

Agents Chemother 2007 May 21; [Epub ahead of print]; Antimicrob Agents Chemother 2007; 51: 2861-

2866.

76. Benator D, Weiner M, Burman W, Vernon A, Zhao Z, Khan AE, Jones BE, Sandman L, Engle M,

Silva-Trigo C, Hsyu PH, Becker MI, and Peloquin CA for the Tuberculosis Trials Consortium. Clinical

Evaluation of the Nelfinavir – Rifabutin Interaction in Patients with HIV Infection and Tuberculosis.


77. Stein GE, Schooley S, Peloquin CA, Missavage A, Havlichek D. Linezolid tissue penetration and

serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin

susceptibility in diabetic patients with foot infections. Journal of Antimicrobial Chemotherapy 2007; 4:

819-823. [E-Published August 1, 2007]

78. Luber A, Browner, R, Kim D, Silverman R, Peloquin CA, Frank I. Steady state pharmacokinetics

(PK) of QD fosamprenavir (FPV)/ritonavir(r) and atazanavir (ATV)/r alone and in combination with

20mg of omeprazole (OMP) in healthy volunteers. HIV Medicine 2007; 8: 457-464.

79. Peloquin CA, Hadad

DJ, Molion LPD, Palaci

M, Boom

WH, Dietze

R, Johnson

JL

Population Pharmacokinetics of Levofloxacin, Gatifloxacin, and Moxifloxacin in Adults with

Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy 2008; 52:852-857. Epub 2007 Dec

10. PMID: 18070980

80. Rosenthal I, Zhang M, Williams

KN, Peloquin

CA, Tyagi S, Vernon AA, Bishai

WR, Chaisson RE,

Grosset JH, Nuermberger

E. Daily dosing of rifapentine cures tuberculosis in three months or less in the

murine model. PLoS Med. 2007 Dec;4(12):e344. PMID: 18092886

81. Am Ende CW, Knudson SE, Liu N, Childs J, Sullivan TJ, Boyne M, Xu H, Gegina Y, Knudson DL,

Johnson F, Peloquin CA, Slayden RA, Tonge PJ. Synthesis and in vitro antimycobacterial activity of B-

ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008; 18: 3029-3033. Epub 2008

Apr 18. PMID: 18457948

82. Schwiesow JN Iseman MD, Peloquin CA. Concomitant use of voriconazole and rifabutin in a

patient with multiple infections. Pharmacotherapy 2008; 28:1076–1080. PMID: 18657024

Charles A. Peloquin



83. Hoff D, Caraway M, Brooks E, Driver E, Ryan G, Peloquin CA, Orme IM, Basaraba RJ, Lenaerts

AJ. Metronidazole lacks antibacterial activity in Guinea Pigs infected with M. tuberculosis.

Antimicrobial Agents and Chemotherapy. 2008; 52: 4137-4140. Epub 2008 Aug 11. PMID: 18694944

84. Wimsatt J, Tothill A, Offermann CF, Sheehy, JG, Peloquin CA. Long-term and per rectum

disposition of clarithromycin in the desert tortoise (Gopherus agassizii). J of the American Association

for Laboratory Animal Science 2008; 47: 41-45. PMID: 18702450

85. Long R, Barrie J, Stewart K, Peloquin CA. Treatment of tuberculous empyema with simultaneous

oral and intra-pleural anti-tuberculosis drugs. Can Respir J. 2008; 15:241-243. PMID: 18716684

86. Dooley K, Flexner C, Hackman J, Peloquin C, Nuermberger E, Chaisson RE, Dorman SE. High-

dose intermittent rifapentine induces its own metabolism and that of moxifloxacin. Antimicrobial

Agents and Chemotherapy. 2008; 52: 4037-4042. Epub 2008 Sep 2. PMID: 18765687

87. Dietz R, Hadad DJ, McGee B. Molino LP, Maciel ELN, Peloquin CA, Johnson DF, Debanne SM,

Eisenach K, Boom H, Palaci M, Johnson JL. Early and Extended Early Bactericidal Activity of

Linezolid in Pulmonary Tuberculosis. Am J Respir Crit Care Med. 2008; 178: 1180-1185. Epub 2008

Sep 11. PMID: 18787216

88. Sung JC, Garcia-Contreras L, VerBerkmoes JL, Peloquin CA, Elbert KJ, Hickey AJ, Edwards DE.

Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrobial Agents and

Chemotherapy 2009; 53: 1338-1343. Epub 2009 Jan 12. PMID: 19139288

89. Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, Peloquin CA, Stout JE.

Therapeutic drug monitoring in patients with tuberculosis and advanced human immunodeficiency virus

infection. Pharmacotherapy 2009; 29: 503–510. PMID: 19397460

90. Sung JC, Garcia-Contreras L, VerBerkmoes JL, Padilla DJ, Peloquin CA, Elbert KJ, Hickey AJ,

Edwards DE. Formulation and Pharmacokinetics of Self-Assembled Rifampicin Nanoparticle Systems

for Pulmonary Delivery. Pharmaceutical Research 2009; 26: 1847-1855. Epub 2009 Apr 30. PMID:

19407933

91. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewll PC, Wells, CD, Reingold

AL, Kenyon TA, Moeti TL, Tappero JW. Isoniazid, Rifampin, Ethambutol and Pyrazinamide

Pharmacokinetics and Treatment Outcomes among a Predominantly HIV-Infected Cohort of

Adults with Tuberculosis – Botswana. Clin Infect Dis. 2009 Jun 15;48(12):1685-94. PMID:

19432554

Charles A. Peloquin



92. McGee B, Dietze R, Hadad DJ, Molino LP, Maciel EL, Boom WH, Palaci M, Johnson JL, Peloquin

CA. Population Pharmacokinetics of Linezolid in Adults with Pulmonary TuberculosisAntimicrob

Agents Chemother. 2009 Sep;53(9):3981-4. Epub 2009 Jun 29. PMID: 19564361

93. Almeida D, Nuermberger

E, Tasneen

R,

Rosenthal

I, Tyagi

S,

Williams

K, Peloquin C, Grosset

J.

Paradoxical effect of isoniazid on the activity of the rifampin-pyrazinamide combination in the mouse

model of tuberculosis. Antimicrob Agents Chemother. 2009 Oct;53(10):4178-84. Epub 2009 Jul 20.

PMID: 19620331

94. Barroso EC, Pinheiro VGF, Facanha MC, Carvalho MRD, Moura ME, Campelo CL, Peloquin CA,

Guerrant RL, Lima AAM. Serum concentrations of rifampin, isoniazid, and intestinal absorption,

permeability in patients with multidrug resistant tuberculosis. Am J Trop Med Hyg. 2009

Aug;81(2):322-9. PMID: 19635892

95. Ahmad Z, Klinkenberg KG, Pinn ML, Fraig MM, Peloquin CA, Bishai WR, Nuermberger EL,

Grosset JG, Karakousis PC. Biphasic Kill Curve of Isoniazid Reveals the Presence of Drug-Tolerant,

Not Drug-Resistant, Mycobacterium tuberculosis in the Guinea Pig. J Infect Dis. 2009 Oct

1;200(7):1136-43.PMID: 19686043

96. Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, Ashkin D, Symes S, Espinoza LA,

Rivero RO, Graham JJ, Peloquin CA. Pharmacokinetic evaluation of rifabutin in combination with

lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis. 2009 Nov

1;49(9):1305-11. PMID: 19807276

97. Luber A, Condoluci D, Slowinski P, Andrews M, Olson K, Peloquin C, Pappa K, Pakes G; for the

COL104422 Study Team. Steady-state amprenavir and tenofovir pharmacokinetics after

coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in

healthy volunteers. HIV Med. 2010 Mar;11(3):193-9. Epub 2009 Oct 23. PMID: 19863619

98. Ahmad Z, Nuermberger EL, Tasneen R, Pinn ML, Williams KN, Peloquin CA, Grosset JH,

Karakousis PC. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea

pig. J Antimicrob Chemother. 2010 Apr;65(4):729-34. Epub 2010 Jan 31. PMID: 20123722

99. Weinberg A, Forster-Harwood J, McFarland E, Pappas J, Davies J, Kinzie K, Barr E, Paul S,

Salbenblatt C, Soda E, Vazquez A, Peloquin CA, Levin M. Kinetics and Determining Factors of the

Virologic Response to Antiretrovirals During Pregnancy. Infect Dis Obstet Gynecol. 2009;2009:621780.

Epub 2010 Jan 10. PMID: 20130816

100. Façanha MC, Gondim AM, Pinheiro VG, Barroso EC, Peloquin CA, Guerrant RL, Lima AA.

Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients

with pulmonary tuberculosis. Braz J Infect Dis. 2009 Jun;13(3):210-7. PMID: 20191199

Charles A. Peloquin



102. Ahmad Z, Pinn ML, Nuermberger EL, Peloquin CA, Grosset JH, Karakousis PC. The potent

bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence

of persisters. J Antimicrob Chemother. 2010 Oct;65(10):2172-5. Epub 2010 Aug 6. PMID: 20693172

103. Ahmad Z, Peloquin CA, Singh RP, Derendorf H, Tyagi S, Ginsberg A, Grosset JH, Nuermberger

EL. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents

Chemother. 2011 Jan;55(1):239-45. Epub 2010 Oct 11. PMID: 20937781

104. De Groote MA, Gilliland JC, Wells CL, Brooks E, Woolhiser LK, Gruppo VR, Peloquin CA,

Orme IM, Lenaerts A. Comparative studies evaluating mouse models used for efficacy testing of

experimental drugs against M. tuberculosis. Antimicrob Agents Chemother. 2011 Mar;55(3):1237-47.

Epub 2010 Dec 6 PMID: 21135176

105. Ahmad Z, Minkowski A, Peloquin CA, Williams K, Grosset JH, Nuermberger EL. Activity of the

fluoroquinolone DC-159a in the initial and continuation treatment of murine tuberculosis. Antimicrob

Agents Chemother. 2011 Apr;55(4):1781-3. Epub 2011 Jan 31. PMID: 21282421

106. Zhang M, Li SY, Rosenthal IM, Almeida DV, Ahmad Z, Converse PJ, Peloquin CA, Nuermberger

EL, Grosset JH. Treatment of Tuberculosis with Rifamycin-containing Regimens in Immune Deficient

MiceAm J Respir Crit Care Med. 2011 May 1;183(9):1254-61. Epub 2011 Feb 17. PMID: 21330452

107. Tasneen R, Li SY, Peloquin CA, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger

EL. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of

tuberculosis. Antimicrob Agents Chemother. 2011; 55: 5485-92. Epub 2011 Sep 19. PMID: 21930883

108. Rhoades JA, Peterson YK, Zhu HJ, Appel DI, Peloquin CA, Markowitz JA. Prediction and in vitro

evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential

source of drug-drug interactions. Pharmaceutical Research. 2012; 29:972-82. Epub 2011 Dec 9. PMID:

22161308

109. Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis WS, Mdluli

KE, Nuermberger EL. Sterilizing activity of novel combinations lacking first- and second-line drugs in a

murine model of tuberculosis. Antimicrob Agents Chemother. 2012 Jun;56(6):3114-20. Epub 2012 Apr

2. PMID: 22470112

110. Tsuji BT, Brown T, Parasrampuria R, Brazeau D, Forrest A, Kelchlin PA, Holden PN, Peloquin

CA, Hanna D, Bulitta J. Front-Loaded Linezolid Regimens Result in Increased Killing and Suppression

of the Accessory Gene Regulator System of Staphylococcus aureus. Antimicrob Agents Chemother.

2012 Jul;56(7):3712-9. Epub 2012 Apr 23. PMID: 22526313

111. Dutta NK, Illei PB, Peloquin CA, Pinn ML, Nuermberger EL and Karakousis PC. Rifapentine is

not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob Agents

Chemother. 2012 Jul;56(7):3726-31. Epub 2012 Apr 30. PMID: 22547623

Charles A. Peloquin



112. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC,

Grosset JH, Nuermberger EL. Dose-ranging comparison of rifampin and rifapentine in two

pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother. 2012 Jun 4.

[Epub ahead of print] PMID: 22664964

113. Tsuji BT, Brown T, Bulitta J, Forrest A, Brazeau D, Kelchlin PA, Holden PN, Peloquin CA,

Skerlos L,Hanna D. Pharmacodynamics of Early, High Dose Linezolid against Vancomycin-Resistant

Enterococci (VRE) with Elevated MICs and Pre-Existing Genetic Mutations. J Antimicrob Chemother.

2012 Jun 8. [Epub ahead of print] PMID: 22685161

114. van Ingen J, Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, Aarnoutse RE, Heifets LB,

Peloquin CA, Daley CL.. The Pharmacokinetics and Pharmacodynamics of Pulmonary Mycobacterium

Avium Complex Disease Treatment. Am J Respir Crit Care Med. 2012 Jun 28. [Epub ahead of print]

PMID: 22744719

115. Matthias KR, Nix DE, Peloquin CA, Graham ML. Poor Absorption of High-Dose Posaconazole in

Pediatric Bone Marrow Transplant Patients. Ann Pharmacother. 2012 Aug 7. [Epub ahead of print]

PMID: 22872751

Charles A. Peloquin


B. Review papers published in refereed journals


1. Nix DE, Goodwin SD, Peloquin CA, Rotella DL, and Schentag JJ. Antibiotic tissue

penetration and its relevance: models of tissue penetration and their meaning. Antimicrobial

Agents and Chemotherapy 1991; 35: 1947-1952.

2. Nix DE, Goodwin SD, Peloquin CA, Rotella DL, and Schentag JJ. Antibiotic tissue

penetration and its relevance: impact of tissue penetration on infection response. Antimicrobial

Agents and Chemotherapy 1991; 35: 1953-1959.

3. Peloquin CA. Therapeutic Drug Monitoring: Principles and Application in Mycobacterial

Infections. Drug Therapy 1992; 22:31-6. Co-circulated in P&T 1992; 17: 1465-1475.

4. Peloquin CA. Controversies in the management of Mycobacterium avium complex (MAC)

infection. Annals of Pharmacotherapy 1993; 27: 928-937.

5. Peloquin CA. Pharmacology of the Antimycobacterial Drugs. Medical Clinics of North

America 1993, 77: 1253-1262.

6. Peloquin CA. Mycobacterial Infections. Pharmacotherapy 1993, 13: 634-639.

7. Peloquin CA, Berning SE. Infections due to Mycobacterium tuberculosis. Annals of


8. Briceland LL, Cleary JD, Fletcher CV, Healy DP, Peloquin CA. Anti-infectives Update.

Annals of Pharmacotherapy 1995; 29: 1035-1040.

9. Peloquin CA, Berning SE. Tuberculosis and multi-drug resistant tuberculosis in children.

Pediatric Nursing 1995, 21: 566-572.

10. Peloquin CA. Therapeutic drug monitoring of the antimycobacterial drugs. Clinics in

Laboratory Medicine 1996; 16: 717-729.

11. Peloquin CA. Mycobacterium avium Complex Infection: Pharmacokinetic and

Pharmacodynamic Considerations That May Improve Clinical Outcomes. Clinical

Pharmacokinetics 1997; 32: 132-144.

12. Peloquin CA. Using therapeutic drug monitoring to dose the antimycobacterial drugs.

Clinics in Chest Medicine 1997; 18: 79-87.

Charles A. Peloquin


B. Review papers published in refereed journals (continued)

13. Amsden GW, Peloquin CA, Berning SE. The role of advanced generation macrolides in the

prophylaxis and treatment of Mycobacterium avium complex (MAC) infections. Drugs 1997, 54:

69-80.

14. Peloquin CA. Contemporary management of tuberculosis. Journal of Infectious Disease


15. Burman WJ, Gallicano K, Peloquin CA. Therapeutic implications of drug interactions in the

treatment of HIV-related tuberculosis. Clinical Infectious Diseases 1999; 28: 419-430.

16. Burman WJ, Gallicano K, Peloquin CA. Comparative pharmacokinetics and pharmacodynamics of

the rifamycin antibiotics. Clinical Pharmacokinetics 2001: 40: 327-341.

17. Peloquin CA. Pharmacological Issues in the Treatment of Tuberculosis. Ann NY Acad Sci 2001;

953: 157-164.

18. Peloquin CA. Therapeutic Drug Monitoring in the Treatment of Tuberculosis. Drugs 2002; 62:

2169-2183.

19. ATS / CDC / IDSA: Treatment of Tuberculosis. Contributor: Peloquin CA. Am J Respir Crit Care

Med. 2003; 167: 603-662.

20. Vaidyanathan S, Peloquin CA, Wyndaele JJ, Buczynski AZ, Almog Y, Hughes P, Soni BM, Singh

G. Amikacin dosing and monitoring in spinal cord injury patients: Variation in clinical practice between

spinal injury units and differences in experts' recommendations. TheScientificWorldJournal 2006; 6:

187-199.

21. Saukkonen JJ, Bernardo J, Cohn D, Gordin F, Jasmer R, Jereb J, Nolan C, Nunes D, Peloquin C,

Shenker S, Sterling T, Strader D, Venkataramanan, R. An official ATS statement: hepatotoxicity of

antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952.

22. Mitnick CD, McGee B, Peloquin CA. Tuberculosis pharmacotherapy: strategies to optimize patient

care. Expert Opin Pharmacother 2009; 10: 381-401. PMID: 19191677

23. Sabarinath SN, Wu B, Peloquin CA, Derendorf H. Pharmacometrics in dose finding of anti-

retroviral and anti-tubercular drugs. Infect Disord Drug Targets. 2011 Apr 1;11(2):157-66. PMID:

21406049

24. Egelund EF, Barth AB, Peloquin CA. Population Pharmacokinetics and its role in Anti-tuberculosis

Drug Development & Optimization of Treatment Curr Pharm Des. 2011 Aug 12. [Epub ahead of print]

PMID: 21834766

Charles A. Peloquin


B. Review papers published in refereed journals (continued)

25. Seddon JA, Hesseling AC, Marais BJ, McIlleron H, Peloquin CA, Donald PR, Schaaf HS.

Paediatric use of second-line tuberculosis agents: a review. Tuberculosis (Edinb). 2011 Nov 24. [Epub

ahead of print] PMID: 22118883

26. Lauzardo M, Peloquin CA. Anti-tuberculosis Therapy for 2012 and Beyond. Expert Opinion On

Pharmacotherapy. [Early Online Feb. 15, 2012]

Charles A. Peloquin

C. Book Chapters

(34 chapters: 17 first author, 16 senior author, 1 other)

1. Peloquin CA, Antituberculosis Drugs: Pharmacokinetics. In Heifets, L, ed. Drug Susceptibility in the

Chemotherapy of Mycobacterial Infections. CRC Press, Boca Raton, 1991, p 59-88.

2. Peloquin CA. Antimicrobial Therapy. In Bittar EE and Bittar N, Eds. Principles of Medical

Biology. Volume 9A: Microbiology. Jai Press, Greenwich, CT, 1997, p 175-198.

3. Berning SE, Peloquin CA. Antimycobacterial Agents: Ethionamide. In Yu VL, Merigan TC,

Barriere S, White NJ, Eds. Antimicrobial Chemotherapy and Vaccines. Williams and Wilkins,

Baltimore, MD, 1998, p 650-654.

4. Berning SE, Peloquin CA. Antimycobacterial Agents: Para-aminosalicylic acid. In Yu VL,

Merigan TC, Barriere S, White NJ, Eds. Antimicrobial Chemotherapy and Vaccines. Williams

and Wilkins, Baltimore, MD, 1998, p 663-668.

5. Berning SE, Peloquin CA. Antimycobacterial Agents: Cycloserine. In Yu VL, Merigan TC,


Baltimore, MD, 1998, p 638-642.

6. Berning SE, Peloquin CA. Antimycobacterial Agents: Isoniazid. In Yu VL, Merigan TC,


Baltimore, MD, 1998, p 654-663.

7. Morris AB, Kanyok TP, Scott J, Peloquin CA, Berning SE. Rifamycins. In Yu VL, Merigan

TC, Barriere S, White NJ, Eds. Antimicrobial Chemotherapy and Vaccines. Williams and

Wilkins, Baltimore, MD, 1998, p 901-963.

8. Peloquin CA, Iseman MD. Antimycobacterial Agents. In Root RK, Ed. Clinical Infectious

Diseases: A Practical Approach. Oxford University Press, New York, NY 1999, p 327-335.

9. Peloquin CA, Ebert SC. Tuberculosis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells

BG, Posey LM, Eds. Pharmacotherapy: A pathophysiologic approach, 4th ed. Appleton &

Lange, Stamford, CT, 1999, p 1717-1736.

10. Peloquin CA, Auclair B. Pharmacology of the second-line antituberculosis drugs. In Portaels F,

Bastian I, Eds. MDR Mycobacterium tuberculosis. Kluwer Academic Publications, Dordrecht, The

Netherlands, 2000, p 163-174.

11. Peloquin CA. Drugs for Tuberculosis. In Piscitelli SC, Rodvold KA, Eds. Drug Interactions

in Infectious Diseases. Humana Press, Totowa, NJ, 2000, p 109-120.

Charles A. Peloquin


C. Book Chapters (continued)

12. Peloquin CA. Tuberculosis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells

BG, Posey LM, Eds. Pharmacotherapy: A pathophysiologic approach, 5th ed., McGraw Hill,

New York, 2002, p 1917-1937.

13. Peloquin CA. Clinical pharmacology of the anti-tuberculosis drugs. Davies PDO, Ed.

Clinical Tuberculosis, 3rd

Ed. Arnold Publishers, London, England, 2003, p 171-190.

14. Namdar R, Peloquin CA. Ethionamide. In Yu VL, Edwards G, McKinnon PS, Peloquin C,

Morse GD, Eds. Antimicrobial Chemotherapy and Vaccines, 2nd

edition, Volume II:

Antimicrobial Agents. Esun Technologies, LLC, 2005, p 533-538.

15. Peloquin CA. Para-aminosalicylic acid. In Yu VL, Edwards G, McKinnon PS, Peloquin C,


edition, Volume II:


16. Peloquin CA. Cycloserine. I In Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD,

Eds. Antimicrobial Chemotherapy and Vaccines, 2nd

edition, Volume II: Antimicrobial Agents.

Esun Technologies, LLC, 2005, p 517-522.

17. Burman WJ, Peloquin CA. Isoniazid. In Yu VL, Edwards G, McKinnon PS, Peloquin C,


edition, Volume II:


18. Namdar R, Morris AB, Peloquin CA. Rifamycins for Nonmycobacterial Infections. In Yu

VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, Eds. Antimicrobial Chemotherapy and

Vaccines, 2nd

edition, Volume II: Antimicrobial Agents. Esun Technologies, LLC, 2005, p 403-

454.

19. Peloquin CA, Vernon A. Antimycobacterial Agents: Rifamycins for Mycobacterial

Infections. In Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, Eds. Antimicrobial

Chemotherapy and Vaccines, 2nd

edition, Volume II: Antimicrobial Agents. Esun Technologies,

LLC, 2005, p 383-402.


BG, Posey LM, Eds. Pharmacotherapy: A pathophysiologic approach, 6th ed. McGraw Hill,

New York, 2005 p 2015-2034.

21. Namdar R, Ebert S, Peloquin CA. Drugs for Tuberculosis. In Piscitelli SC, Rodvold KA,

Eds. Drug Interactions in Infectious Diseases, 2nd

Edition. Humana Press, Totowa, NJ, 2006, p

191-214.

Charles A. Peloquin



22. Nuermberger EL, Grosset JH, Peloquin CA. Pharmacological Issues in the Development of

New Antituberculosis Drugs. Development of New Antituberculosis Drugs. Yew WW, Ed. Nova

Science Publishers, Hauppauge NY, 2006, p 53-73.

23. Peloquin CA, Namdar R. Tuberculosis. In Chisholm-Burns MA, Wells BG,

Schwinghammer TL, Malone PM, Kolesar JM, Rotschafer JC, DiPiro JT Eds. Pharmacotherapy:

principles and practice. McGraw Hill, New York, 2008. p 1105-1116.

24. Peloquin CA. Clinical pharmacology of the anti-tuberculosis drugs. Davies PDO, Barnes PF,

Gordon SB, Ed. Clinical Tuberculosis, 4th Ed., Hodder Arnold, London, 2008


BG, Posey LM, Eds. Pharmacotherapy: A pathophysiologic approach, 7th ed. McGraw Hill,

New York, 2008 p 1839-1856.

26. Namdar R, Peloquin CA. Tuberculosis. In Pharmacotherapy in Primary Care, Linn WD,

Wofford MR, O;Keefe ME, Posey LM, Eds. McGraw Hill, New York, 2008 p 463-473.

27. Namdar R, Morris AB, Peloquin CA. Rifamycins for Nonmycobacterial Infections. In Yu

VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, editors. Antimicrobial Chemotherapy

and Vaccines Vol II: Antimicrobial Agents 2008. Pittsburgh; Esun Technologies, LLC.

Available from: http://www.antimicrobe.org/index.asp

28. Namdar R, Peloquin CA. Ethionamide. In Yu VL, Edwards G, McKinnon PS, Peloquin C,

Morse GD, editors. Antimicrobial Chemotherapy and Vaccines Vol II: Antimicrobial Agents

2010. Pittsburgh; Esun Technologies, LLC. Available from:

http://www.antimicrobe.org/index.asp

29. Peloquin CA, Namdar R. Tuberculosis. In Chisholm-Burns MA, Wells BG,

Schwinghammer TL, Malone PM, Kolesar JM, Rotschafer JC, DiPiro JT Eds. Pharmacotherapy:

principles and practice, 2nd

Ed. McGraw Hill, New York, 2010. p 1253-1263.

30. Peloquin CA, Namdar R. Tuberculosis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR,

Wells BG, Posey LM, Eds. Pharmacotherapy: A pathophysiologic approach, 8th ed. McGraw

Hill, New York, 2011 p 1931-1949.

31. Egelund EF, Peloquin CA. Current Issues in Tuberculosis Pharmacokinetics. In Donald PR,

van Helden PD, Eds. Antituberculosis Chemotherapy. Prog Respir Res. Basel, Karger, 2011, vol

40, pp 153–160.

Charles A. Peloquin



32. Namdar R, Peloquin CA. Drugs for Tuberculosis. In Piscitelli SC, Rodvold KA, Pai MP

Eds. Drug Interactions in Infectious Diseases, 3rd

Edition. Humana Press, c/o Springer

Science+Business Media, LLC, 233 Spring Street, New York, NY, 2011, p 401-424.

33. Barth AB, Egelund EF, Peloquin CA. Rifamycin Use in HIV-infected Patients with Tuberculosis.

Yi-Wei Tang, Ed. Recent Translational Research in HIV/AIDS. InTech, Rijeka, Croatia. 2011.

ISBN 978-953-307-719-2

34. Namdar R, Peloquin CA. Tuberculosis. In PSAP VII Infectious Diseases, ACCP, Lenexa, KS 2012,

p. 53-74.

Charles A. Peloquin


D. Other Publications


1. Peloquin CA. Stereospecific approaches in the synthesis of phenethanolamine analogues.

Honors Thesis. University of Connecticut School of Pharmacy. December, 1981

2. Peloquin CA. Trimethoprim-Sulfamethoxazole. Drug Information Bulletin, Duke University

Medical Center. March, 1983.

3. Peloquin CA. Trimethoprim-Sulfamethoxazole. Patient Information Article. North Carolina

Medical Journal. 1983; 44: 438.

4. Peloquin CA. Beta-Lactam antibiotics and bleeding disorders. Drug Information Bulletin,

Duke University Medical Center. February, 1984.

5. Nix, DE, Peloquin CA. Storing extra calibration curves in the TDx assay system. Clinical

Pharmacy 1988; 7: 792.

6. Peloquin CA. Fighting Tuberculosis with Old Weapons. DICP, The Annals of


7. Peloquin CA. The Dosing of Antimycobacterial Agents (Letter). Clinical Pharmacy 1991; 10:

664-665.

8. Peloquin CA. Shortages of Antimycobacterial Drugs (Letter). New England Journal of

Medicine 1992; 326: 714.

9. Berning SE, Huitt GA, Iseman MD, Peloquin CA. Malabsorption of Anti-tuberculosis

medications by a patient with AIDS (Letter). New England Journal of Medicine 1992; 327:

1817-1818.

10. Peloquin CA, MacPhee AA, Berning SE. Malabsorption of antimycobacterial medications.

New England Journal of Medicine 1993; 329: 1122-1123.

11. Peloquin CA, Berning SE. Comment: Intravenous Streptomycin (letter). Annals of

Pharmacotherapy 1993, 27: 1546-1547.

12. Peloquin CA. Book Review. Tuberculosis: Pathogenesis, Protection, and Control. Annals of

Pharmacotherapy 1995, 29: 1054.

13. Berning SE, Peloquin CA. Adverse events associated with high-dose rifabutin in macrolide-

containing regimens for the treatment of Mycobacterium avium complex lung disease. (letter)

Clinical Infectious Diseases 1996; 22: 885.

Charles A. Peloquin


D. Other Publications (continued)

14. Peloquin CA. Treatment and Prophylaxis of Disseminated Mycobacterium avium Complex

Infections in Patients with AIDS (DMAC). (editorial) Drug Benefit Trends 1996; 8: 16-17.

15. Peloquin CA. Quinolones and Tuberculosis (editorial). Annals of Pharmacotherapy 1996;

30: 1034-1035.

16. Peloquin CA, Berning SE. Advice on the treatment of drug-resistant tuberculosis. (letter)

Am J Health-Syst Pharm. 1997; 54: 700-701.

17. Peloquin CA, Berning SE. Advice on the treatment of Mycobacterium avium complex

infection. (letter) Am J Health-Syst Pharm 1997; 54: 1208-1209

18. Peloquin CA, Berning SE, Huitt GA, Iseman MD. Levofloxacin for drug-resistant

Mycobacterium tuberculosis. (letter) Annals of Pharmacotherapy 1998; 32: 268-269.

19. Peloquin CA. Serum Concentrations of the Antimycobacterial Drugs (editorial) Chest 1998;

113: 1154-1155.

20. Peloquin CA. Rifampin Stability (letter). Therapeutic Drug Monitoring 1998; 20: 450-451.

21. Peloquin CA. Therapeutic Drug Monitoring in Antituberculosis Chemotherapy (letter).

Therapeutic Drug Monitoring 1999; 21: 426-427.

22. Peloquin CA, Berning SE, Huitt GA, Iseman MD. (letter) AIDS and TB drug absorption.

International Journal of Tuberculosis and Lung Disease 1999; 3: 1143-1144.

23. Peloquin CA. Tuberculosis Drug Serum Levels (letter). Clinical Infectious Diseases 2001; 33: 584-

585.

24. Peloquin C. What is the right dose of rifampin? Int J Tuberc Lung Dis 2003; 7: 3-5.

25. Goldberg S, Hanson D, Peloquin CA. Rifamycin treatment for tuberculosis in a patient on atenolol:

less interaction with rifabutin than with rifampin. (letter) Clinical Infectious Diseases 2003; 37: 607-608.

26. Peloquin C. Use of Therapeutic Drug Monitoring in Tuberculosis Patients (editorial) Chest 2004;

126: 1722-1724.

27. Peloquin CA, Durbin D, Childs J, Sterling TR, Weiner M. Stability of Anti-Tuberculosis Drugs

Mixed in Food. Clinical Infectious Diseases 2007; 45: 521.

28. Peloquin C. Aminoglycoside nephrotoxicity. (letter) Antimicrob Agents Chemother. 2010; 54:

2750-2751. PMID: 20480959

Charles A. Peloquin


D. Other Publications (continued)

29. Stein GE, Smith CL, Peloquin CA, Mosher B, Dybas L, Kepros JP. Bile and Gallbladder Tissue

Concentrations of Moxifloxacin in Patients with Acute Cholecystitis. Ann Pharmacother. 2010 Jun 15.

[Epub ahead of print] PMID: 20551298

30. Peloquin CA Pharmacokinetic Mismatch of Tuberculosis Drugs. Antimicrob. Agents Chemother.

2012, 56:1666.

31.Egelund EF, Peloquin CA. Pharmacokinetic variability and TB treatment outcomes, including

acquired drug resistance. Invited Editorial. Clin Infect Dis. 2012 May 4. [Epub ahead of print] PMID:

22467672

Charles A. Peloquin

E. Manuscripts Accepted for Publication

Egelund EF, Egelund

TA, Ng

JS,

Wassil

SK, Peloquin CA.

Posaconazole pharmacokinetics in a two year

old with rhino-cerebral zygomycosis—A case report and review of the literature. Pharmacother

F. Chapters Accepted for Publication

Peloquin CA, Namdar R. Tuberculosis. In Chisholm-Burns MA, Wells BG, Schwinghammer TL,

Malone PM, Kolesar JM, Rotschafer JC, DiPiro JT Eds. Pharmacotherapy: principles and practice, 3rd

Ed. McGraw Hill, New York

G. Manuscripts Submitted for Publication

Glover TL, Goodin BR, Horgas AL, Kindler LL, King CB, Sibille K, Peloquin CA Riley III, JR, Staud

R, Bradley LA, Fillingim RB. Vitamin D, Race, and Pain

Revised 8-12

charles arthur peloquin, pharm.d. curriculum vitae · charles a. peloquin page 7 bibliography...

Documents